Compare ABT & WFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABT | WFC |
|---|---|---|
| Founded | 1888 | 1852 |
| Country | United States | United States |
| Employees | N/A | 200999 |
| Industry | Medical/Dental Instruments | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.9B | 224.7B |
| IPO Year | 2006 | N/A |
| Metric | ABT | WFC |
|---|---|---|
| Price | $90.50 | $84.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 18 |
| Target Price | ★ $130.90 | $96.59 |
| AVG Volume (30 Days) | 8.9M | ★ 12.0M |
| Earning Date | 04-16-2026 | 04-14-2026 |
| Dividend Yield | ★ 2.76% | 2.21% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $44,328,000,000.00 | N/A |
| Revenue This Year | $10.75 | $11.08 |
| Revenue Next Year | $8.10 | $4.76 |
| P/E Ratio | $145.40 | ★ $14.15 |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $81.97 | $72.59 |
| 52 Week High | $137.49 | $97.76 |
| Indicator | ABT | WFC |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 67.59 |
| Support Level | $84.96 | $78.04 |
| Resistance Level | $92.73 | $87.59 |
| Average True Range (ATR) | 1.83 | 1.75 |
| MACD | 0.47 | 0.70 |
| Stochastic Oscillator | 69.96 | 96.69 |
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Wells Fargo is a premier, North American-focused banking titan that commands a $2.2 trillion balance sheet and the third-highest deposit market share in the United States. The bank uses a dense, expansive network of 4,093 branches to champion retail consumers and the middle market, where the firm has built a particularly strong reputation. Following the removal of its federal asset cap in 2025, the firm is set to deploy its legacy excess liquidity to expand each of its four segments: consumer & business lending, commercial banking, corporate & investment banking, and wealth & investment management.